• 1.

    Gardner CL, Ryman KD, 2010. Yellow fever: a reemerging threat. Clin Lab Med 30: 237260.

  • 2.

    Monath TP, Vasconcelos PF, 2015. Yellow fever. J Clin Virol 64: 160173.

  • 3.

    World Health Organization , 2019. Yellow Fever Situation Report. Available at: https://www.who.int/en/news-room/fact-sheets/detail/yellow-fever. Accessed September 24, 2020.

  • 4.

    Thomas RE, 2016. Yellow fever vaccine-associated viscerotropic disease: current perspectives. Drug Des Devel Ther 10: 33453353.

  • 5.

    da Saúde Brasil Ministério, em Saúde Secretaria de Vigilância, Epidemiológica Departamento de Vigilância, 2020. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação, 4th edition. Brasília, Brazil: Ministério da Saúde.

    • Search Google Scholar
    • Export Citation
  • 6.

    Martins RM et al., 2014. Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine 32: 66766682.

    • Search Google Scholar
    • Export Citation
  • 7.

    O’Grady JG, Alexander GJ, Hayllar KM, Williams R, 1989. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97: 439445.

    • Search Google Scholar
    • Export Citation
  • 8.

    Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, Barban V, 2008. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 151: 4046.

    • Search Google Scholar
    • Export Citation
  • 9.

    Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29: 45444555.

    • Search Google Scholar
    • Export Citation
  • 10.

    Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE, 2016. Adverse events reports following yellow fever vaccination, 2007–13. J Travel Med 23: 16.

    • Search Google Scholar
    • Export Citation
  • 11.

    Martins RM, Leal MLF, Homma A, 2015. Serious adverse events associated with yellow fever vaccine. Hum Vaccin Immunother 11: 21832187.

  • 12.

    Gershman MD et al., 2012. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 30: 50385058.

    • Search Google Scholar
    • Export Citation
  • 13.

    Kohl KS et al., 2007. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 25: 56715674.

    • Search Google Scholar
    • Export Citation
  • 14.

    Seligman SJ, 2011. Yellow fever virus vaccine-associated deaths in young women 1891–1893. Emerg Infect Dis 17: 18911893.

  • 15.

    Whittemburry A et al., 2009. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27: 59745981.

  • 16.

    Pan American Health Organization , 2013. Viscerotropic Disease Associated with Yellow Fever: Case Studies. Washington, DC: PAHO.

Past two years Past Year Past 30 Days
Abstract Views 935 935 33
Full Text Views 119 119 1
PDF Downloads 134 134 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Case Report: Fatal Viscerotropic Disease in a Young Woman Following Yellow Fever Vaccination

View More View Less
  • 1 Department of Pathology and Forensic Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
  • | 2 Division of Epidemiological Surveillance, Secretaria Municipal de Saúde, Ribeirão Preto, São Paulo, Brazil;
  • | 3 Division of Intensive Care Medicine, Department of Surgery and Anatomy, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
  • | 4 Infectious Diseases Division, Department of Internal Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil
Restricted access

ABSTRACT.

Yellow fever is a viral hemorrhagic disease, and vaccination is the most effective way to minimize the impact of the disease. Serious adverse events after yellow fever vaccination are rare. We report the case of a young woman with an unusual presentation of yellow fever 17DD vaccine-associated acute viscerotropic disease, with severe hepatic impairment following a long incubation period. She died more than a month after yellow fever vaccination.

Author Notes

Address correspondence to Mariângela Ottoboni Brunaldi, Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Av. dos Bandeirantes 3900, 14049-900 - Ribeirão Preto, São Paulo, Brazil. E-mail: mabrunaldi@fmrp.usp.br

Financial support: This work was supported by São Paulo Research Foundation (FAPESP-N°2003/07959-0).

Authors’ addresses: Mariângela Ottoboni Brunaldi, René Julias Costa Silva, and Alexandre Todorovic Fabro, Department of Pathology and Forensic Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil, E-mails: mabrunaldi@fmrp.usp.br, renejulias@yahoo.com.br, and fabro@fmrp.usp.br. Daniel Cardoso de Almeida e Araujo, Division of Epidemiological Surveillance, Secretaria Municipal de Saúde, Ribeirão Preto, São Paulo, Brazil, E-mail: dacaraujo@alumni.usp.br. Anibal Basile-Filho, Maria Auxiliadora-Martins, Mayra Gonçalves Menegueti, and Maria Isabel Beloddi, Division of Intensive Care Medicine, Department of Surgery and Anatomy. University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil, E-mails: abasile@fmrp.usp.br, mamartins@hcrp.usp.br, mayramenegueti@usp.br, and bel_ft@yahoo.com.br. Danillo Lucas Alves Esposito and Benedito Antônio Lopes da Fonseca, Infectious Diseases Division, Department of Internal Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil, E-mails: esposito@usp.br and bfonseca@usp.br.

Save